The aim of this prospective study was to compare the two prognostic tests uPA/PAI-1 and EPclin with regard to feasibility, risk stratification, and impact of the test result on adjuvant therapy recommendation in hormone-sensitive, HER2 negative breast cancer with 0–3 positive lymph nodes. The gene discussed is PLAU; the disease is breast cancer.